RE:RE:RE:RE:Analyst on Market Call Just Now Asked About ConcordiaIf you were an accountant, you would know that the equity is worth nothing, the debt may be as well. Restructuring will happen next. I called it, just like the shorts called the CMA investigation FIVE MONTHS ago and you cried "short and distort" boo hoo baggie.
adamchess wrote: Yes, you are not an accountant if you cannot differentiate between GAAP and non-GAAP measurements and the benefit to analysis that each provides. Maybe you should dwell on that instead of whether someone adds a question mark on the end of his comments.
Health123 wrote: adamchess, these were the analyst's comments, not mine so why don't you discuss with him. And why do you always put question marks at the end of your end statements. Does it matter if he knew. If he didn't know then he didn't do his due diligence buying AMCo and is a dumbfuccck that you have been defending. If he did know than that makes it a bigger and badder biz than Valeant. So don't know what point you are trying to make. The equitty is worth zero when you look at the market cap and debt. You aren't really an accountant are you? You are a Baggie who believes non-GAAP (er.. I mean "Adjusted" non=-GAAP" so stop blaming the shorts for stealing your money. You sound as pathetic as Thompson is.
adamchess wrote: I do not support price gauging but since when does government determine prices of goods in a free market economy? Maybe the Brits should have bought AMCo from Cinven if they were concerned about drug prices. And taken on the debt as well of course. Not sure how you can things both ways. The bad guy in this picture was Cinven, a Brit firm, who started this price gauging thing rolling. Not even sure if MT was wise enough to know about these things
? I am fairly certain they will work out something that doesn't put the company under... yet again, who knows anything for sure
? Health123 wrote: "High debt... Future uncertain... Do not see any reversal. Grew business by acquistions and raising prices and that is over. Factor sales in the UK and weak pound. Too much risk. Democratic election may do what UK is doing with drug pricing. Competition and Market Authority now investigating."